Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro

• Published in: Cell death & disease Vol. 11; no. 11; p. 984
• Main Authors: Dituri, Francesco, Scialpi, Rosanna, Schmidt, Tannin A., Frusciante, Martina, Mancarella, Serena, Lupo, Luigi Giovanni, Villa, Erica, Giannelli, Gianluigi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 16.11.2020; Springer Nature B.V
• Subjects: 13/1; 13/106; 13/109; 13/31; 13/51; 13/95; 38/109; 38/77; 631/67/1059/602; 692/308/2778; Antibodies; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biochemistry; Biomedical and Life Sciences; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - pathology; CD44 antigen; Cell adhesion & migration; Cell Biology; Cell Culture; Cell migration; Cell proliferation; Extracellular matrix; Fibroblasts; Hepatocellular carcinoma; Humans; Immunology; Inhibitor drugs; Life Sciences; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; mRNA; Phenylurea Compounds - pharmacology; Phenylurea Compounds - therapeutic use; Proteoglycans; Proteoglycans - pharmacology; Proteoglycans - therapeutic use; Pyridines - pharmacology; Pyridines - therapeutic use; Sorafenib - pharmacology; Sorafenib - therapeutic use; Targeted cancer therapy; Transforming growth factor-b; Tumor Microenvironment

Sorafenib and regorafenib administration is among the preferential approaches to treat hepatocellular carcinoma (HCC), but does not provide satisfactory benefits. Intensive crosstalk occurring between cancer cells and other multiple non-cancerous cell subsets present in the surrounding microenvironm...